Abstract
Introduction: Since the introduction of the Corona pandemic, the use of appropriate antivirals with minimal side effects has been the most important research topic. Laboratory evidence has shown that ivermectin, which has long been available as an anti-parasitic drug market, has anti-COVID19 properties. Therefore, in this study, we investigated the outcomes of this agent administration in patients undergoing mechanical ventilation. Material and method: Intubated patients with Covid 19 who were eligible for the study were randomly divided into two groups: 1) ivermectin recipient (n = 31) and 2) placebo group (n = 29). This study was performed in Center Corona hospitals in Ahvaz from March 2020 to September 2021. Mortality event was Primary outcome; vital signs and pulmonary Compliance were as secondary outcomes of the study. Results: The results of the study did not show a significant difference between the two groups in demographic data including: age, sex, and time of intubation after the onset of symptoms, plasma levels of LDH, ESR, CRP, D-Dimer and IL-6. Survival analysis did not show a significant difference between the mortality event in the two groups.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
